비호지킨씨 림프종에서 CAMP-MOB 복합화학요법의 치료효과
Treatment of Intermediate-grade Non-Hodgkin's Lymphomas with CAMP-MOB Combination Chemotherapy
대한암학회지 1992년 24권 1호 p.102 ~ 108
소속 상세정보
서창인
김홍태/신동복/이재훈/허대석/방영주/박선양/김병국/김노경
KMID : 0360319920240010102
Abstract
Between January 1988 to December 1988, the CAMP-MOB combination chemotherapy (cyclophosphamide 400mg/m* day 1-10, methotrexate 200mg/m* IV day 8, vincristine 1.4mg/m* IV day 14, and bleomycin 15mg/m* day 14 every 3 weeks) had been administered in
20
patients with intermediate grade non-Hodgkin's lymphomas.
Complete remission rate was 80% and the median remission duration of complete responders was 20 months. The median survival of overall patients was 23 months and two year survival rate was 50%(two year disease-free survival rate: 35%). Complete
responders had a prolonged survival in comparison with partial responders or non-responders, but other factors such as the stage.'B' symptom, LDH level, bone marrow involvement didn't influence remission duration or overall survival.
Non-hematologic toxicity was mild and manageable but hematologic toxicity was significant, with two treatment-related deaths.
Based on these findings, we concluded that CAMP-MOB combination chemotherapy could induce complete remission in high proportion of intermediate-grade non-Hodgkin's lymphoma patients, However, because of short remission duration, it had no
advantages
over the other regimens in terms of overall and disease-free survival.
키워드
원문 및 링크아웃 정보
등재저널 정보